metformin + vildagliptin

This refers to the pharmacological management arm of a clinical study conducted by Seoul National University Hospital, comparing oral anti-diabetic drugs (OADs) to autologous islet transplantation in patients who developed postoperative diabetes mellitus following distal pancreatectomy. The regimen specifically involves the use of metformin as first-line therapy, with the addition of vildagliptin (a DPP-4 inhibitor) if glycemic control is insufficient. Metformin works by reducing hepatic glucose production and improving insulin sensitivity, while vildagliptin enhances insulin secretion and suppresses glucagon release by inhibiting the degradation of incretin hormones.

Other names

oral anti-diabetic drugsOADsmetformin and vildagliptin regimen